Plasma levels of inflammatory cytokines in adult Nigerians with the metabolic syndrome

Udenze Ifeoma Christiana, Amadi E. Casimir1, Awolola Awodele Nicholas2, Makwe C. Christian3, Ajie I. Obiefuna

INTRODUCTION

Metabolic syndrome was first described by Reaven3 in 1988 when he described the clustering of metabolic abnormalities of insulin resistance (IR)/glucose intolerance, hypertension, dyslipidemia (high triglyceride and low high-density lipoprotein [HDL] cholesterol concentrations) and obesity in one individual. The components of the syndrome are risk factors for atherosclerosis, making metabolic syndrome a significant risk for coronary heart disease.2 Obesity and IR also provide significant risk for developing type 2 diabetes.1 Reaven called it the IR syndrome because he believed that IR accounted for every component of the syndrome.1

Other new features have been added to the metabolic syndrome criteria over time such as increased plasminogen.
Current concepts on the pathophysiology of the metabolic syndrome have it that inflammation is the link between abdominal obesity, IR and the metabolic syndrome. Tumor necrotic factor alpha (TNF-α) and interleukin 6 (IL-6) are proinflammatory cytokines which have been linked with abdominal obesity and the metabolic syndrome. IL-6 has been linked with increased production of CRP in the liver, atherosclerosis, and cardiovascular mortality. Current concepts of insulin as an anti-inflammatory hormone have been reported and impairment of insulin action in IR occasioned by the proinflammatory state of excess adiposity would explain the link between abdominal obesity, IR, and the metabolic syndrome.

There are few studies on the relationship between inflammation and the metabolic syndrome in adult Nigerians. This study aims to determine the plasma levels of IL-6, TNF-α, and CRP in adult Nigerians with the metabolic syndrome and to determine the relationship between components of the metabolic syndrome and CRP in adult Nigerians. The awareness of the importance of inflammation in the metabolic syndrome may help to develop new strategies for the prevention and treatment of metabolic syndrome and related disorders.

SUBJECTS AND METHODS

This case–control study consisted of fifty adult men and women with the metabolic syndrome and fifty age- and sex-matched males and females without the metabolic syndrome. The diagnosis of the metabolic syndrome was based on the NCEP-ATPIII criteria. The subjects with metabolic syndrome were drawn from patients attending the Obesity and Metabolic Clinic of the Lagos University Teaching Hospital and the controls were members of staff of the hospital. The Ethical Research and Review Committee of the Hospital approved the study protocol, and informed consent was obtained from the participants.

The inclusion criterion was adult males and females between 30 and 70 years of age. Known diabetics were excluded from the study. The study participants reported on the morning of the study after an overnight (10–12 h) fast. Five milliliters of venous blood was collected from the antecubital vein.

Abdominal obesity was determined by measurement of the waist circumference in centimeters using the pubic crests and the umbilicus as landmarks. The hip circumference was measured from the farthest point on the gluteus using the anatomical neck of the femur as landmarks. The blood pressure was determined using the Accoson’s Mercury Sphygmomanometer (cuff size 15 cm × 43 cm). The subjects were seated and rested for 30 min before measurement. The systolic blood pressure was taken at the first Korotkoff sound and diastolic at the fifth Korotkoff sound. The average of two readings taken 15 min apart was used.

The total, low-density lipoprotein (LDL), HDL cholesterol, triglyceride, and glucose concentrations were determined on fasting serum samples using reagents from Randox Laboratories Limited, Antrim, UK, BT 29 4QY, on semiautomatic biochemistry analyzer BS3000P-Sinnowa Medical Science and Technology Company Limited, Nanjing, China (211135). Serum levels of IL-6, TNF-α, CRP, and insulin were determined using reagents from Biowend Laboratories, 62100 Brno, Czech Republic by an enzyme-linked immunosassay technique on Acurex Plate Read - Acurex Diagnostics, Ohio, USA (419-872-4775). IR was calculated using the homeostasis model assessment for IR formula: (Fasting glucose [mmol/L] × (fasting insulin [μU/mL])/22.5.

The data were analyzed using the statistical package for the Social Sciences Software (version 20.0; SPSS Inc., Chicago, IL) package. Independent Student’s t-test was used to test the differences in the mean values for the continuous variables. Chi-square test was used to test the differences in the proportion of the categorical variables. Regression analysis was used to determine the association between variables. Statistical significance was set at P < 0.05.
RESULTS

The study population included twenty men and thirty women with metabolic syndrome mean age of 47.84 ± 6.4 years and age and sex matched controls. Table 1 shows the sociodemographic characteristics of the study participants.

The age- and sex-matched cases and controls did not differ in their sociodemographic characteristics.

Table 2 shows the clinical and laboratory characteristics of the study participants.

The age- and sex-matched cases and controls differed in some of the metabolic syndrome parameters. The inflammatory markers, IL-6, TNF-α and CRP, were significantly higher in the group with metabolic syndrome.

Table 3 shows the regression of CRP on components of the metabolic syndrome.

There was an association between CRP and waist circumference, HDL and IR.

DISCUSSION

This study reports significantly elevated levels of the proinflammatory cytokines IL-6, TNF-α and the acute phase protein, CRP, in the subjects with metabolic syndrome compared to the control subjects without metabolic syndrome. This is similar to the findings by Indulekha et al. and Choi et al. reported significantly higher sensitivity CRP levels in elderly Korean women with impaired glucose tolerance compared to controls with normal glucose tolerance but also reported comparable levels of TNF-α and IL-6 in women with and without impaired glucose tolerance. Kitsios et al. carried out a study on obese young adults and reported elevated IL-6 levels but comparable TNF-α levels between obese and normal weight young adults. The different study populations, the different criteria for defining metabolic syndrome as endorsed by different organizational bodies, and the different combinations of dysmetabolic features that characterize the syndrome may account for some of the observed differences from these studies. A recurring factor from these studies, however, is an increase in the concentration of one or more markers of inflammation in relation to the different components that make up the syndrome.

The reason for the inflammation in the metabolic syndrome is not yet fully understood. An explanation may be that larger adipose tissue mass in obesity leads to increased release of IL-6 and TNF-α into the circulation which in turn accounts for a greater production of CRP by the liver. Another possibility is that IR itself is responsible for the higher production of the cytokines.

These reports corroborate our findings in this study of a positive association between CRP and waist circumference,
a surrogate marker for abdominal obesity, and IR in the metabolic syndrome.

The original description of the metabolic syndrome by Reaven1 consisted of a clustering of dysmetabolic features accounted for by resistance to the classic metabolic functions of insulin. Thus, hyperinsulinemia, glucose intolerance, type 2 diabetes, hypertriglyceridemia, and low HDL concentrations can be accounted for by resistance to the actions of insulin on glucose and carbohydrate metabolism.17 The defects of insulin action in glucose metabolism include failure to suppress gluconeogenesis in the liver and failure to mediate glucose uptake in insulin-sensitive tissues (i.e., muscle and adipose tissue). To compensate for defects in insulin action, insulin secretion must be increased to sustain euglycemia, leading to a state of hyperinsulinemia. Failure of this compensatory mechanism will result in glucose intolerance and hyperglycaemia.17

In the adipocytes, insulin enhances the incorporation of free fatty acids into triglycerides by its activation of lipoprotein lipase, insulin also inhibits the activity of hormone sensitive lipase thereby decreasing the efflux of free fatty acids from adipocytes.18 In a state of IR, the adipocytes are resistant to the effects of insulin. The increased free fatty acid flux to the liver causes increased hepatic very LDL (VLDL) production. A higher proportion of triglyceride is transferred from the triglyceride-rich VLDL to LDL and HDL by the cholesterol ester transfer protein. The hydrolysis of the triglyceride-rich LDL produces a preponderance of small dense HDL particles that is filtered by the kidney resulting in low HDL concentrations.19 The increased free fatty acid flux worsens the insulin resistant state through specific actions that block insulin signal transduction.4

The finding of increased CRP levels and an association between CRP, a marker of inflammation and the metabolic syndrome components of waist circumference, IR and low HDL, a marker of cardiovascular risk, in this study, supports reports from other studies of the inclusion of elevated levels of CRP as a new feature associated with the metabolic syndrome.4,8

Current concept of insulin as an anti-inflammatory hormone and obesity as a proinflammatory condition provide a conceptual framework with which to place a substantial number of apparently unrelated biological events into a pathophysiological construct and account for the link between inflammation, abdominal obesity, IR, and cardiovascular disease in the metabolic syndrome.19

Novel nonmetabolic actions of insulin as an anti-inflammatory hormone have been supported by recent observations that insulin has been shown to suppress several proinflammatory transcription factors and the genes regulated by them,20,21 an impairment of insulin action in IR would thus lead to the activation of these proinflammatory transcription factors and expression of their corresponding genes. Further studies have also shown that insulin reduced the plasma concentrations of CRP and other inflammatory mediators in subjects with type 2 diabetes and severe hyperglycaemia22,23 and recent observations on the interference of insulin signal transduction by inflammatory mechanisms in obesity further supports the inflammation hypothesis.24

Observations made in the USA on patients with the metabolic syndrome, who were being treated for inflammatory arthritis, with the anti-inflammatory drug etanercept, revealed that the patients had reduced levels of CRP and other inflammatory cardiovascular risk markers following weeks of therapy.25 This underscores the place of inflammation in the metabolic syndrome and its potential for therapy for metabolic syndrome and related disorders.

CONCLUSION

This study reports an increase in inflammatory mediators in the metabolic syndrome. It also shows a statistically significant association between CRP and some components of the metabolic syndrome. Inflammation may have a role to play in the pathogenesis of the disorder.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

REFERENCES

1. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.
2. Ninomiya JK, L’Italien G, Criqui MH, Whyte JL, Gamst A, Chen RS. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third
National Health and Nutrition Examination Survey. Circulation 2004;109:42-6.
3. Klein BE, Klein R, Lee KE. Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in Beaver Dam. Diabetes Care 2002;25:1790-4.
4. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: A comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005;111:1448-54.
5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
6. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640-5.
7. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-53.
8. Sharma P. Inflammation and the metabolic syndrome. Indian J Clin Biochem 2011;26:317-8.
9. Jiang CQ, Lam TH, Liu B, Lin JM, Yue XJ, Jin YL, et al. Interleukin-6 receptor gene polymorphism modulates interleukin-6 levels and the metabolic syndrome: GBCS-CVD. Obesity (Silver Spring) 2010;18:1969-74.
10. Wannamethee SG, Whincup PH, Rumley A, Lowe GD. Inter-relationships of interleukin-6, cardiovascular risk factors and the metabolic syndrome among older men. J Thromb Haemost 2007;5:1637-43.
11. Moreira PF, Dalboni MA, Cendoroglo M, Santos GM, Cendoroglo MS. Postprandial interleukin-6 response in elderly with abdominal obesity and metabolic syndrome. J Nutr Health Aging 2013;17:206-10.
12. Langenberg C, Bergstrom J, Scheidt-Nave C, Pfeilschifter J, Barrett-Connor E. Cardiovascular death and the metabolic syndrome: Role of adiposity-signaling hormones and inflammatory markers. Diabetes Care 2006;29:1363-9.
13. Wild D. Immunoassay Handbook. London: Stockton Press; 1996. p. 339.
14. Indulekha K, Surendar J, Mohan V. High sensitivity C-reactive protein, tumor necrosis factor-a, interleukin-6, and vascular cell adhesion molecule-1 levels in Asian Indians with metabolic syndrome and insulin resistance (CURES-105). J Diabetes Sci Technol 2011;5:982-8.
15. Choi KM, Lee J, Lee KW, Seo JA, Oh JH, Kim SG, et al. Comparison of serum concentrations of C-reactive protein, TNF-alpha, and interleukin 6 between elderly Korean women with normal and impaired glucose tolerance. Diabetes Res Clin Pract 2004;64:99-106.
16. Kitsios K, Papadopoulos M, Kosta K, Kadoglou N, Chatzidimitriou D, Chatzopoulou F, et al. Interleukin-6, Tumor necrosis factor a and metabolic disorders in youth. Int J Endocrinol Metab 2012;2:120-7.
17. Reaven GM. Insulin resistance, compensatory hyperinsulinemia, and coronary heart disease: Syndrome X revisited. In: Jefferson LS, Cherrington AD, editors. Handbook of Physiology, Sec. 7. The Endocrine System, The Endocrine Pancreas and Regulation of Metabolism. Vol. II. New York: Oxford University Press; 2001. p. 1169-97.
18. Ginsberg HN, Huang LS. The insulin resistance syndrome: Impact on lipoprotein metabolism and atherothrombosis. J Cardiovasc Risk 2000;7:325-31.
19. Dandona P, Aljada A, Bandyopadhyay A. Inflammation: The link between insulin resistance, obesity and diabetes. Trends Immunol 2004;25:4-7.
20. Dandona P, Aljada A, Mohanty P, Ghanim H, Hamouda W, Assian E, et al. Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: Evidence for an anti-inflammatory effect? J Clin Endocrinol Metab 2001;86:3287-65.
21. Aljada A, Ghanim F, Mohanty P, Kapur N, Dandona P. Insulin inhibits the pro inflammatory transcription factor, early growth response gene-1 (Erg)-1 expression in mononuclear cells (MNC) and reduces plasma tissue factor (TF) and plasminogen activator inhibitor (PAI-1) concentrations. J Clin Endocrinol Metab 2002;87:1419-22.
22. Takebayashi K, Aso Y, Inukai T. Initiation of insulin therapy reduces serum concentrations of high-sensitivity C-reactive protein in patients with type 2 diabetes. Metabolism 2004;53:693-9.
23. Stentz FB, Umbierrez GE, Cuervo R, Kitabchi AE. Proinflammatory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crises. Diabetes 2004;53:2079-86.
24. Vozarova B, Weyer C, Hanson K, Tataranni PA, Bogardus C, Pratley RE. Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes Res 2001;9:414-7.
25. Bernstein LE, Berry J, Kim S, Canavan B, Grinspoon SK. Effects of etanercept in patients with the metabolic syndrome. Arch Intern Med 2006;166:902-8.